Bret Crumpton, DO
Ophthalmology · Columbus, GANPI 1437112935
Payments from drug & device makers
Across 373 payments — averaging $36.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Sun Pharmaceutical Industries Inc.$2K
- Alcon$2K
- Aerie Pharmaceuticals, Inc.$1K
- Sight Sciences, Inc.$899
- Bausch & Lomb Americas Inc.$801
- plus $3K from 23 others
What the payments were for
- Consulting fees$1,57011%
- Food & beverage$11,77185%
- Education$1541%
- Gifts$640%
- Entertainment$2282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $3,719 |
| Sun Pharmaceutical Industries Inc. | 50 | $2,224 |
| Alcon | 56 | $1,849 |
| Aerie Pharmaceuticals, Inc. | 7 | $1,013 |
| Sight Sciences, Inc. | 40 | $899 |
| Bausch & Lomb Americas Inc. | 20 | $801 |
| Glaukos Corporation | 14 | $465 |
| Tarsus Pharmaceuticals, Inc. | 15 | $399 |
| Nova Eye, Inc. | 3 | $333 |
| Rxsight Inc | 3 | $305 |
| Kala Pharmaceuticals, Inc. | 4 | $207 |
| NEW World Medical,inc. | 5 | $202 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $184 |
| Shire North American Group Inc | 3 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $137 |
| Thea Pharma Inc. | 7 | $136 |
| Tearlab Corp | 1 | $118 |
| Ocular Therapeutix, Inc. | 4 | $93 |
| Harrow Eye, LLC | 3 | $93 |
| Akorn Operating Company LLC | 4 | $86 |
| Oyster Point Pharma, Inc. | 3 | $80 |
| Amgen | 3 | $67 |
| Novartis | 3 | $66 |
| Iridex Corporation | 5 | $60 |
| Eyepoint US, Inc. | 1 | $24 |
| Akorn, Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$820
- Rocklatan$820
- RESTASIS$750
- CEQUA$731
- XIIDRA$498
- VYZULTA$396
- MIEBO$380
- LUMIGAN$375
- Clareon$369
- XEN GLAUCOMA TREATMENT SYSTEM$289
- OMNI(R) SURGICAL SYSTEM (US)$255
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- DURYSTA$244
- LenSx$153
- enVista MX60 IOL$149
- STELLARIS ELITE$149
- INVELTYS$141
- EYSUVIS$141
- COMBIGAN$125
- XDEMVY$125
How this compares
$13,787 in reported general payments places this provider in the 85th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 623 | $335,353 |
| RestasisCyclosporine | 206 | $262,812 |
| RocklatanNetarsudil Mesylat/Latanoprost | 239 | $155,073 |
| CombiganBrimonidine Tartrate/Timolol | 328 | $136,246 |
| Alphagan PBrimonidine Tartrate | 173 | $81,322 |
| RhopressaNetarsudil Mesylate | 125 | $72,215 |
| CequaCyclosporine | 63 | $52,793 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 204 | $34,698 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 88 | $25,936 |
| XiidraLifitegrast | 17 | $25,698 |
| Brimonidine Tartrate | 357 | $24,552 |
| Prednisolone Acetate | 374 | $22,700 |
| Cyclosporine | 23 | $22,441 |
| Brinzolamide | 102 | $21,264 |
| MieboPerfluorohexyloctane/Pf | 14 | $15,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $3,719 | $815,7331,330 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $1,013 | $227,288364 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $2,224 | $52,79363 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $801 | $40,84831 claims |
| AlconSimbrinza, Azopt | $1,849 | $31,804101 claims |
| NovartisIlevro | $66 | $14,94830 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $184 | $14,26153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Columbus
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.